PURPOSE: Raf/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling pathway is constitutively activated in melanoma. AZD6244 blocks MEK1/2, inhibiting ERK phosphorylation. We focus on associated cutaneous toxicity and we attempt to understand the underlying pathophysiology and design treatment strategies. EXPERIMENTAL DESIGN: Dermatologic conditions of 22 patients with unresectable melanoma stage III/IV in a phase II trial were evaluated. Thirteen patients received AZD6244 initially, and nine patients were treated with AZD6244 following tumor progression with temozolomide. Biopsies were compared with matched controls in normal skin. Immunohistochemistry was performed. Half-side treatment of acute...
Purpose: To examine mechanisms that determine long-term responses of B-RAF<sup>V600E</sup> melanoma ...
PURPOSE: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAP...
Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease....
Purpose: Disseminated melanoma is highly therapy resistant. The finding that 66% of melanomas harbor...
Abstract Purpose: Disseminated melanoma is highly therapy resistant. The finding that 66% of melanom...
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; Astra...
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; Astra...
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; Astra...
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; Astra...
Purpose: Conjunctival melanoma (CM) is a rare but lethal form of cancer. Similar to cutaneous melano...
Melanoma, the deadliest form of skin cancer, is characterized by aberrant hyperactivation of the ERK...
PURPOSE: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAP...
PURPOSE: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAP...
EGFR inhibitors used in oncology therapy modify the keratinocyte differentiation processes, impairin...
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have...
Purpose: To examine mechanisms that determine long-term responses of B-RAF<sup>V600E</sup> melanoma ...
PURPOSE: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAP...
Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease....
Purpose: Disseminated melanoma is highly therapy resistant. The finding that 66% of melanomas harbor...
Abstract Purpose: Disseminated melanoma is highly therapy resistant. The finding that 66% of melanom...
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; Astra...
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; Astra...
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; Astra...
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; Astra...
Purpose: Conjunctival melanoma (CM) is a rare but lethal form of cancer. Similar to cutaneous melano...
Melanoma, the deadliest form of skin cancer, is characterized by aberrant hyperactivation of the ERK...
PURPOSE: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAP...
PURPOSE: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAP...
EGFR inhibitors used in oncology therapy modify the keratinocyte differentiation processes, impairin...
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have...
Purpose: To examine mechanisms that determine long-term responses of B-RAF<sup>V600E</sup> melanoma ...
PURPOSE: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAP...
Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease....